9vHPV vaccine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Papillomavirus Infections
Conditions
Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms, Adenocarcinoma in Situ, Condylomata Acuminata
Trial Timeline
Jun 29, 2018 → Jan 29, 2019
NCT ID
NCT03546842About 9vHPV vaccine
9vHPV vaccine is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03546842. Target conditions include Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms.
What happened to similar drugs?
4 of 20 similar drugs in Papillomavirus Infections were approved
Approved (4) Terminated (0) Active (16)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05450705 | Phase 3 | Active |
| NCT05314023 | Phase 3 | Active |
| NCT05285826 | Phase 3 | Active |
| NCT04772534 | Phase 3 | Completed |
| NCT04708041 | Phase 3 | Active |
| NCT04199689 | Phase 3 | Active |
| NCT03546842 | Phase 3 | Completed |
| NCT01651949 | Phase 3 | Completed |
Competing Products
20 competing products in Papillomavirus Infections